^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    CELsignia test

    Company:
    Celcuity
    Type:
    Laboratory Developed Test

    Details

    Evidence
    News
    The CELsignia platform identifies patients with abnormal oncogenic signaling pathways to detect new treatment options for patients. CELsignia Test measures dynamic HER2, c-Met, and PI3K-node involved signaling activity in the living tumor cells of HER2-negative breast cancer patients. CELsignia tests provide pharmaceutical companies a new type of biomarker, dysregulated signaling activity, to identify additional patients eligible for their targeted therapies.
    Cancer:
    Breast Cancer
    Gene:
    HER-2 (Human epidermal growth factor receptor 2), MET (MET proto-oncogene, receptor tyrosine kinase)